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Abstract
Viruses are the eventual assertion of parasitism, they not only take nutriments 
from the host cell, apart from that they direct its metabolic machinery to amalgam-
ate novel virus particle and to diminish the ability of flu viruses to reproduce in an 
individual antiviral drugs are used. When used as directed, antiviral drugs may 
help to lessen the duration of flu symptoms and may reduce the severity of com-
mon flu symptoms. Antiviral drugs are the class of drugs which comes under the 
antimicrobials, and that also accommodates the larger group i.e. of antibiotics. They 
are broad-spectrum in nature and can be effective against a wide range of viruses. 
They can be used as a single drug as well as in combination of drugs. Antiviral 
drugs are dissimilar from the antibiotics, they do not demolish their target pathogen 
ideally they obstruct development of pathogen. To the greatest extent antiviral 
drugs currently accessible are delineate to deal with herpes viruses, covid-19, HIV, 
the hepatitis b and c viruses herpes simplex, small pox, picornavirus and influenza 
a and b viruses etc. Scientists are searching to drag out the range of antiviral to the 
other families of pathogens. They mainly act by inhibiting the attachment of viruses 
on cells, prevent genetic reproduction of virus, prevent viral protein production and 
vital for production of virus. The emanation of antiviral is generally the outcome 
about an appreciably expanded skills or proficiency of the generative, microscopic 
and atomic activity of organisms, allowing biomedical analyst to acknowledge 
the structure, mechanism of action and activity of viruses, significant progress 
within the procedure for come across the current drugs. Coronavirus 2019 (COVID 
19) is highly infectious disease triggered by SARS-CoV-2 (severe acute respira-
tory syndrome) coronavirus 2 causing nearly 2.9 million deaths worldwide. With 
the emergence of SARS-CoV-2, the repurposing of antiviral drugs has come into 
picture.
Keywords: Parasitism, Broad spectrum, Genetic development of virus,  
Target pathogen, Viral protein production
1. Introduction
Severe Acute Respiratory Syndrome Coronavirus also known as SARS- CoV, 
a medical condition arises due to viral infection of SARS-CoV. It was proved to 
be major threat to human civilization in 21st century was declared as pandemic 
by World Health Organization in March 2020 as the exposure of this syndrome 
affected the human life cycle poorly causing deaths at an average of 10 percent 
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of the affected population globally. This was first emerges in the Wuhan (a state 
of China) in December 2019 and later on feast globally by the transmission from 
affected person to the other person through physical contact [1, 2] and later on 
when it was established and discovered, the first preventive measure was social 
distancing which came into force February 2020 according to WHO guidelines 
and other coronavirus like MERS (Middle east respiratory syndrome) in 2017 and 
Covid-19 which emerges before 2020.
1.1 Symptoms of SARS
Symptoms of COVID-19 are homogenous to influenza to some extent, and it also 
causes a pneumonia type symptom, which has been seen in many patients through-
out the world. The patients who have fallen ill are reported to suffered cough mainly 
with sputum, high temperature of the body, difficulties while breathing, headache 
and sore throat, shaking chills, and diarrhea.
1.2 Structure of coronavirus
SARS-CoV belongs to Coronaviridae family having spherical enveloped particle 
containing positive stranded RNA that binds to nucleocapsid present inside the 
membrane protein having glycoprotein spike in the envelop [3, 4] further explained 
in Figure 1.
1.3 Phases of development of SARS
As a virus, it also confiscates the host body system and then multiplies via viral 
attachment, fusion, penetration; uncoating, transcription, translation, and virion 
release. [5]
Figure 1. 
Mechanism action of coronavirus.
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Pathway used to combat SARS through direct inhibition of coronavirus either 
by inhibiting the vital viral protein corresponds to genome reproduction or else by 
impeding viral entry into eukaryotic cells. In second place, by modulating immune 
system either by boosting the immediate response or by inhibiting the inflamma-
tory response [6].
2. Antiviral drugs
Although viral infections have been disclosed since earliest times, it was only 
during the nineteenth century that scientists were able to isolate “the filterable 
particles”, later called viruses. Viruses are the infectious agent that reproduces only 
inside the living cell and they can infect all types of living cells and direct the cell 
to produce more viruses. They are smaller than the bacteria’s. The entire infectious 
virus particle, called a virion, consists of the nucleic acid and an outer shell of pro-
tein. Antiviral drugs are classified as the medicines which are mainly used to treat 
viral infection. Many of the antiviral drugs target the specific viruses and they are 
considered as the broad spectrum drugs. Most viral infections rectify spontaneously 
in immunocompetent individuals. The objective of antiviral therapy is to diminish 
the symptoms and infectivity additionally to shorten the duration of illness [7]. 
These drugs react by arresting the viral replication cycle at numerous stages. Most 
of the antiviral drugs currently available are used to treat infections caused by HIV, 
herpes viruses, hepatitis Band C viruses, and influenza A and B viruses, and C 
viruses, and influenza A and B viruses etc. Designing effective and safe antiviral 
drugs is difficult as viruses use host cells to replicate. It is back-breaking to find 
targets for drugs that would affect only viruses leaving host cells. Viral variation is 
also one of the reasons posing difficulty in the development aof antiviral drugs and 
vaccines. Furthermore, antiviral drugs are classified as non-retroviral and retroviral 
drugs which act on the different types of viruses and stop their further growth or 
their replication and these results in the cure of viral disease [8]. Coronavirus 2019 
(COVID 19) is highly infectious disease triggered by SARS-CoV-2 (severe acute 
respiratory syndrome coronavirus 2 causing nearly 2.9 million deaths worldwide 
Currently, a variety of antiviral drugs are in clinical trails to treat SARS-CoV-2 
which inhibit viral replication.
3. Classification of viruses
3.1 ICTV classification
The ICTV evolves the current classification system and wrote guidelines that put 
a bigger weight on certain virus properties to maintain family consistency. A unified 
taxonomy has been accepted. Solitary a little part of the entire variety of viruses has 
been studied. Till 2019 ICTV explained 9 kingdoms, 4 realms, 2 subphyla, 16 phyla, 
36 classes, 55 orders, 9 suborders, 168 families, 10 sub-families, 1421 genera, 68 
subgenera and 6589 species of viruses. [9]
The general taxonomic structure of ranges of taxon and the suffixes used in 
taxonomic names are mentioned under. Till 2019, the ranks of sub realm, subking-
dom and subclass are unemployed whereas all ranks are in usage.
Realm (−viria), Subrealm (vira), Kingdom (−virae), Subkingdom (−virites), 
Phylum (−viricota), Subphylum (−viricotina), Class (−viricetes), Subclass (−viriceti-
dae), Order (−virales), Suborder (−virineae), Family (−viridae), Subfamily (−viri-
nae), Genus (−virus), Subgenus (−virus) [10].
Biotechnology to Combat COVID-19
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3.2 Baltimore classification
This is based on the mechanism of mRNA production. Viruses produce proteins 
from their genomes and replicate themselves. Viral genome can be single-stranded 
(ss) and or double stranded (ds). ssRNA viruses may be either antisense (−) or 
sense (+). [11] Viruses are classified in seven groups:
i. ssDNA viruses (+strand or sense) DNA (e.g., Parvovirus)
ii. dsDNA viruses (e.g., Adenovirus, Poxvirus)
iii. dsRNA viruses (Reovirus)
iv. (+) ssRNA viruses (+ strand or sense) RNA (e.g. Coronavirus,Picornavirus)
v. (−) ssRNA viruses (+ strand or antisense) RNA (e.g.Orthomyxovirus, 
Rhabdovirus)
vi. dsDNA-RT viruses DNA with RNA intermediate in life cycle (e.g., 
Hepadnavirus)
vii. ssRNS-RT viruses (+strand or sense) RNA with DNA intermediate in life 
cycle (eg. Retroviruses)
3.3 Based on their shape
Viruses are present in various sizes and shapes (Figure 2), but are composed 
of two vital components i.e., a core of genetic material, either RNA or DNA and a 
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polyhedral and complex Coronaviruses have positive stranded RNA (+ssRNA) with 
crown like structure possessing spike glycoproteins on the envelop. [12].
4. Evolution
A virus is a tiny parasite, infectious substance of small size and basically struc-
ture that can multiply only in living cells of plants, animals or bacteria etc. The 
name is derived from a Latin word meaning “poison.” Highly viruses have either 
RNA or DNA as their genetic material. The nucleic acid of viruses may be single 
or double stranded. The complete infectious virus element, called a virion, com-
prises of the nucleic acid and an outer shell is made up of protein [13]. Identifying 
evolving viruses are those that are freshly appeared or have recently expanded in 
predominance and/or geographical range uncovers several vital vague patterns. 
Primary virtually all emerging viruses have RNA more readily than DNA genomes. 
RNA viruses are more customarily familiar than DNA viruses. Additionally, 
almost all emergent viruses have an animal reservoir, such that the process of 
viral emergence can frequently be categorized as cross-species transmission. The 
extremely substantial exception for the rule is that cross-species transmission is 
central to viral emergence is HCV, which was first identified in 1989 but which is 
expected to have a considerably extended history in human populations [14]. In 
numerous cases, the specific cause of emergence, why the virus has traversed from 
animals and obsessed by humans can be assigned to ecological factors, involving 
to alterations in land use and deforestation. Although a multitude of such factors 
exist, either variations in the proximity of the donor and recipient populations, 
so that humans have an amplified coincidental of exposure to animal pathogens 
and variations in the size and density of the donor and recipient populations result 
in increase in both the exposure and the probability that continued networks 
of transmission will be established once a virus has inserted into a new species. 
Although biologists have assembled huge amount of knowledge how present day 
viruses evolve. When investigating the evolutionary history of most organisms, 
scientists can look at fossil record and homogenous historic evidence. While 
many of the viruses do not have the single ancestors. Generally recognizing the 
significance of ecology, it is also possible that genetic factors, whether in the host 
or further probably the virus, contribute to the process of disease emergence. As 
observed with other RNA viruses, SARS-CoV-2 is undergoing genetic mutations 
while adapting to new individual hosts. Several variants are reported, however 
only few are affecting public health. In United Kingdom, VOC 202012 (B.1.1.7 
lineage) was described in December 2020 followed by B.1.351 lineage (501Y.V2) in 
South Africa. B.1.1.248/B.1.1.28/P1 (or 501Y.V3) was reported in Brazil in January 
2021 and recently in California B.1.427/B.1.429 is discovered. As per WHO, 7 
variants are of interest viz. B.1.525, B.1.526, B.1.427/B.1.429, B.1.1.28.2 alias P2, 
B.1.1.28.3, alias P.3 and B.1.616 [15].
5. How virus replicate
As viruses are obligate pathogen they cannot replicate on their own but they 
need the host to replicate and produce multiple copies of them. This typically occurs 
by the virus inserting its genetic material in host cells, co-opting the proteins to cre-
ate viral replicates, until the cell bursts from the high volume of new viral particles.
There are six fundamental stages that are essential for viral replication 
(Figure 3).








1. Attachment: This stage involves the interaction between the virus and host cell 
surface, there they interact with receptors peculiar to them and their host cells. 
This is also known as the tropism of a virus.
2. Penetration: The attachment to the specific receptor can produce conforma-
tional changes in the viral capsid protein that lead the way to the viral and 
cellular membranes fusing. Some DNA viruses can also undertake into the host 
cell through receptor-mediated endocytosis.
3. Uncoating: Once inside the cell, the first step is uncoating. This process requires 
the viral capsid degrading, either by the action of viral or host enzymes and 
release of genomic information takes place. This enables the start of replication 
through transcription or translation for RNA or DNA viral genomic informa-
tion, respectively. The result of the replication step is the synthesis of the viral 
genome and proteins.
4. Replication: this process is different both in RNA and DNA viruses and also in 
viruses with dissimilar nucleic acid polarity. This procedure terminates in de 
novo synthesis of genome and viral proteins.
Figure 3. 
Stages of viral replication.
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5. Assembly: After de novo synthesis of viral proteins and genome, which can be altered 
post-transcriptionally, viral proteins are wrapped with newly replicated viral genome 
into new virions that are unconfined from host cells. This process is called maturation.
6. Virion Release: There are two mechanisms of viral freeing: lysis or budding. After virion 
release some viral proteins remain within the host’s cell membrane, which acts as poten-
tial targets for circulating antibodies. [16].
CoVs are positive stranded RNA enveloped viruses. Upon entry into the host, 
viral RNA replication begins with synthesis of polyprotein 1a/1ab(pp1a/pp1ab). 
By the synthesis of subgenomic RNAs sequences and replication-transcription 
complex, transcription occurs. Termination of transcription occurs at transcription 
regulatory sequences. Six open reading frames (ORF) are present on CoV genome. 
Frameshift between ORF 1a and ORF1b helps in production of both pp1a and pp1ab 
polypeptides which are further processed by chymotrypsin like protease (3CLpro) 
or main protease or may include papain like proteases which produces non-
structural proteins (NSPs 1–16). Besides ORF1a and ORF1b, other ORFs encode 
structural proteins including nuclecapsid proteins, membrane, envelope, spike and 
accessory proteic chains [17]. Dedicated sgRNAs translate accessory and structural 
proteins. Researchers have also reported NSPs in stalling hosts immunity [18]. The 
envelop plays crucial role in viral pathogenesis as it encourages viral release and 
assembly. [19]
5.1 Classification of antiviral drugs
Anti-viral drugs and their activity mention in Table 1.
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<15% oxidized to 
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5% topical






2. Penciclovir Penciclovir is a 
synthetic acyclic 
guanine derivative
Following single or 
repeat application 
of the 1% cream at 
a dose of 180 mg 
penciclovir daily.













3. Amantadine An antiviral that 
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4. Rimantadine An RNA synthesis 
inhibitor that is used 
as an antiviral agent
Well absorbed, 
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are the major metabolic pathways.
40% Less than 25% of 
the dose excreted 
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atom replaces the 




12 adult patients 
was 86% ± 16% 
(mean ± SD) for 
the 150-mg tablet 
and 87% ± 13% for 
the oral solution
The only known metabolite of 
lamivudine is the trans-sulfoxide 
















malaise and fatigue, 
nasal signs and 
symptoms, diarrhea, 
and cough
6. Ribavirin Ribavirin is a 
synthetic guanosine 
nucleoside and 
antiviral agent that 
interferes with the 




64% following a 
single oral dose 
administration of 
600 mg ribavirin
It is phosphorylated by adenosine 
kinase to ribavirin mono-, di-, 
triphosphate metabolites. After 
activation and function, it undergoes 
metabolic pathways where it is 
reversibly phosphorlyated or 
degraded via deribosylation and 













7. Zidovudine A dideoxynucleoside 
compound in which 
the 3′-hydroxy group 
on the sugar moiety 













65% (range, 52 to 
75%)
Hepatic. Metabolized by 
glucuronide conjugation to 






















Sr. No. Name of Drugs Description Absorption Metabolism Protein 
Binding
Clearance Dose Toxicity
8. Didanosine Didanosine is a 
potent inhibitor of 
HIV replication, 
acting as a chain-
terminator of viral 










intracellularly to its active 
moiety, 2,3-dideoxyadenosine-5-
triphosphate (ddA-TP). It is then 
further metabolized hepatically to 
yield hypoxanthine, xanthine, and 
uric acid
Low (<5%) Renal clearance 400 mg/day
250 mg/day














a single dose 
administration 
is 93 ± 9% for a 
50 mg tablet and 
91 ± 8% for an oral 
solution
nevirapine is extensively 
biotransformed via cytochrome 






Renal clearance 200 mg/day oral to 
be increased after 








vomiting, and weight 
decrease
10. Ritonavir Ritonavir is an HIV 
protease inhibitor 
that interferes with 
the reproductive 
cycle of HIV. 
Although it was 
initially developed 










Ritonavir circulates in the plasma 
predominantly as unchanged 
drug. Five metabolites have been 
identified. The cytochrome P450 
enzymes CYP3A and CYP2D6 are 
the enzymes primarily involved in 
the metabolism of ritonavir.
~98–99% The apparent oral 
clearance at steady-
state is 8.8 ± 3.2 L/h






11. Indinavir A potent and specific 
HIV protease 
inhibitor that 
appears to have good 
oral bioavailability
Rapidly absorbed Hepatic. Seven metabolites have 
been identified, one glucuronide 
conjugate and six oxidative 
metabolites
60% Less than 20% 
of indinavir 
is excreted 
unchanged in the 
urine
800 mg TDS Symptoms of overdose 
include myocardial 
infarction and angina 
pectoris.




























Sr. No. Name of Drugs Description Absorption Metabolism Protein 
Binding
Clearance Dose Toxicity
12. Efavirenz It is a non-nucleoside 
reverse transcriptase 
inhibitor (NNRTI) 
and is used as part 
of highly active 
antiretroviral 
therapy (HAART)





(Cmax) of 4.07 
mcg/ml 3–5 hours 
following 600 mg 
standard adult oral 
dose.
Efavirenz is principally metabolized 
by the cytochrome P450 system 




Nearly all of 
the urinary 
excretion of the 
radiolabeled drug 
was in the form of 
metabolites
600 mg OD on 
empty stomach
The most common 
adverse effects with 
efavirenz therapy are 
central nervous system 
symptoms, rash and 
hepatitis
13. Raltegravir Raltegravir is an 
antiretroviral drug
Absorbed from the 
gastrointestinal 
tract




Anti-viral drugs and their activity [17–21].
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3. Anti-hepatitis virus drugs
A. For hepatitis B
• Lamivudine
• Tenofovir




















5. Ccr-5 receptor inhibitor
• Maraviroc
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6. Mechanism of action of non- retroviral drugs
6.1 Anti-Herpes drugs
The recognition of acyclovir and penciclovir has leaded the way evolution 
of a fortunate systemic therapy for medicating herpes simplex virus infection. 
Acyclovir is a nucleotide analogue antiviral which is used to treat against her-
pes simplex. It is generally used as the first line drug in the treatment viruses. 
Acyclovir is converted into acyclovir monophosphate due to the action of viral thy-
midine kinase. Acyclovir monophosphate is further converted to the diphosphate 
form by guanylate kinase. Acyclovir diphosphate is become acyclovir triphosphate 
by help of nucleoside diphosphate kinase. Acyclovir triphosphate effectively binds 
to viral DNA polymerase than cellular DNA polymerase and enters into DNA 
where 2′ and 3′ carbon leads to DNA chain termination. Acyclovir stronger affin-
ity for viral DNA polymerase did not allow other bases to bind it, making them 
inactive [20].
Dose and Preparation: 200 mg 5 times a day oral (15 mg/kg/day), 5–10 mg/kg 8 
hourly by slow i.v. infusion, 5% topical application 6 times a day; ZOVIRAX 200 mg 
tab, 250 mg/vial for i.v. injection; CYCLOVIR 200 mg tab, 5% skin cream; HERPEX 
200 mg tab, 3% eye ointment, 5% skin cream; OCUVIR 200, 400, 800 mg tab, 3% 
eye ointment, ACIVIR-DT 200, 400, 800 mg tab.
Toxicity: Symptoms of overdose include agitation, coma, seizures, lethargy, and 
precipitation in renal tubules. These symptoms are more unsophisticated in patients 
given high doses without monitoring of fluid and electrolyte balance or reduced 
kidney function.
6.2 Anti-influenza virus drugs
• As per CDC four antiviral drigs are approved by FDA against influenza virus.
• Relenza (zanamivir)
• Tamiflu (oseltamivir phosphate)
• Rapivab (peramivir)
• Xofluza (baloxavir marboxil)
• Amantadine and rimantadine were approved long back ago to cure influenza 
A virus infection. But new strains of influenza like 2009 H1N1 are resistant to 
these drugs. Zanamivir acts by inhibition of influenza virus neuraminidase 
thereby altering particle release and aggregation. It renders the virus inactive 
by making it unable to break into host cells and infect others [21].
Dose and Preparation: Therapeutic Dose 10 Mg Bd By Inhalation; Prophylactic 
Dose 10 Mg Od; Relenza 5 Mg Per Actuation Powder Inhaler.
Biotechnology to Combat COVID-19
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Toxicity: The toxicology studies illustrated that zanamivir has very little toxicity 
and no drug-specific toxicities were observed in animal toxicity studies.
Arbidol which is popularly used to cure influenza is reported to inhibit SARS-
CoV-2 [22]. Similarly, Favipiravir, an anti-influenza drug, also is undergoing clinical 
trials against COVID19 [23].
6.3 Anti-hepatitis virus drugs
To date, two classes of antiviral drugs have been accepted by the Food and Drug 
Administration for the treatment of hepatitis B, and nucleos(t)ide analogs (lamivu-
dine, telbivudine, adefovir, tenofovir [TDF] and for hepatitis C, immunomodula-
tors (interferon [IFN]-α and pegylated-interferon [PEG-IFN]-α). Lamivudine, 
a synthetic nucleoside analogue, is phosphorylated intracellularly to lamivudine 
triphosphate, 5′-triphosphate metabolite. The nucleoside analogue is inserted into 
viral DNA by HBV polymerase and HIV reverse transcriptase leading to DNA chain 
termination. Interferons are glycoproteins synthesized by host cells in response to 
viral infection and some other inducers. These are effective against DNA and RNA 
virus and have a no-specific inhibitory effect on the viral replication against a wide 
variety of unrelated viruses [24].
Dose and Preparation: For Chronic Hepatitis B 100 Mg Od; For Hiv Infection 
150 Mg Bd (Along With Other Antiretroviral Drugs); Lamivir 150 Mg Tab, 
150 Mg/5 Ml Solution; Lamivir-Hbv 100 Mg Tab; Heptavir, Lamidac, Lamuvid 
100, 150 Mg Tabs.
Toxicity: The most common reported adverse reactions in adults were headache, 
nausea, malaise and fatigue, nasal signs and symptoms, diarrhea, and cough etc.
Remdesivir which was developed to treat Hepatitis C has also demonstrated 
antiviral activity against SARS-CoV-2 [25]. As per results of controlled, randomized 
clinical trials, remdesivir has shortened the time of recovery in adults employed 
to treat hospitilized COVID-19 patients [26–30]. However, remdesivir potential 
against new SARS-CoV-2 variants is under trail and should be monitored.
Ribavirin used to cure COVID-19 [31] approved to cure respiratory syncytial 
virus and HCV leads to anemia at higher dose [32]. Ribavirin is administered 
intravenously at a dose of 500 mg, 2–3 times a day [33].
Some Antiretroviral Combinations:
1. Lamivudine 150 Mg + Zidovudine 300 Mg Table (1 Tab Bd); Combivir, Cyto-
com, Duovir, Lamuzid, Zidolam Table.
2. Lamivudine 150 Mg + Stavudine 30 Mg Or 40 Mg Table (1 Tab Bd); Lamivir-S, 
Lamostad, Virolis Table.
3. Lamivudine 150 Mg + Zidovudine 300 Mg + Nevirapine 200 Mg Table (1 Tab 
Bd); Duovir-N, Cytocom-N, Nexivir-Z.
7. Mechanism of action of retroviral drugs.
7.1 Nucleoside reverse transcriptase inhibitors (NRTIS)
The nucleotide/nucleoside reverse transcriptase inhibitors are the first class 
of antiretroviral drugs approved by FDA. NRTIS are taken up by host cells and 
phosphorylated and activated by cellular kinases. NRTIS lack 3′-hydroxyl group at 
the 2’deoxyribosyl moiety and have nucleotide/nucleoside as base. They prevent the 
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formation of 3′-5′-phosphodiester bond in DNA chains thus preventing the replica-
tion of virus. An important aspect these drugs is that they inhibit the production of 
either negative or positive strands of DNA if incorporated during DNA- dependent 
DNA synthesis or RNA-dependent DNA synthesis. [34].
Dose and Preparation: Didanosine: 400 Mg/Day (For >60 Kg Bw), 250 Mg/Day 
(< 50 Kg Bw); 1 Hour Before or 2 Hours After Meals; Dinex Ec, Dd Retro, Virosine 
Dr. 250, 400 Mg Tabs. Zidovudine (Azidothymidine, AZT): Adults 300 mg BD; 
Children 180 mg/m2 (max 200 mg) BD. Retrovir, Zidovir 100 Mg Cap 300 Mg Tab, 
50 Mg/5 Ml Syr, Zidomax, Zydowin 100 Mg Cap, 300 Mg Tab (To Be Taken With 
Plenty Of Water).
Toxicity: Symptoms of overdose include fatigue, headache, nausea, and vomit-
ing. LD50 is 3084 mg/kg (orally in mice).
7.2 Non-nucleoside reverse transcriptase inhibitor (NNRTIS)
These are second class of reverse transcriptase inhibitors. They act by binding 
to reverse transcriptase and create hydrophobic pocket proximal to active site. This 
pocket generates novel spatial configuration of substrate binding site to decrease 
the overall activity of polymerase. By producing different configuration, synthesis 
of DNA slows down. NNRTIS are not effective against HIV-2 reverse transcriptase, 
because of non-competitive inhibitor action.
Dose and Preparation: Nevirapine: 200 mg/day oral to be increased after 2 weeks 
to 200 mg BD; Nevimune, Nevivir, Nevipan, Neviretro 200 Mg.
Toxicity: Symptoms of overdose include edema, erythema nodosum, fatigue, 
fever, headache, insomnia, nausea, pulmonary infiltrates, rash, vertigo, vomiting, 
and weight decrease. The most common adverse reaction is rash.
8. Protease inhbitor (PIs)
The HIV viral proteinase enzyme which always fragment the replicative and struc-
tural proteins which evolve from major HIV genes mormally as gag and pol, is restrain 
by Ritonavir. Ritonavir inhibits the cleavage of gag-pol polyprotein leading in non-
infectious immature viral particles. Ritonavir is also potent inhibitor of cytochrome 
P450 CYP3A4 isoenzyme which is present in both liver and small intestine. It is type 
II ligand which binds into CYP3A4 and further irreversibly to heme iron via thiazole 
nitrogen linkage which reduces proteins redox potential and impedes its reduction 
with cytochrome P450 reductase, redox partner. Ritonavir may edge cellular transport 
and efflux of other protease inhibitor via MRP efflux channel and P-glycoprotein.
Ritonavir/ Lopinavir is FDA approved therapy to treat HIV and is also reported 
to treat COVID19. However in patients with severe COVID-19, this combination 
showed no benefit [35].
PREPARATIONS: RITOVIR 250 mg tab, RITOMUNE, RITOMAX 100 mg cap.
Entry inhibitors obstruct HIV entry into CD4 cells in organism cells. They act 
in a different way other than nucleoside reverse transcriptase inhibitors, protease 
inhibitors and non-nucleoside reverse transcriptase inhibitors which function after 
they it has infected CD4 cells. They work by taking themselves to proteins which is 
composed of amino acids on superficial side of CD4 cells, the proteins present on 
surface of CD4 cells or on the surface of HIV. The proteins on HIV outer coat must 
bind to proteins present on the surface of CD4. Entry proteins inhibit the above 
process.
PREPARATION: - Efavirenz: is available as 600 mg tab, also FFERVEN, 
VIRANZ, and EVIRENZ, 200 mg cap, 600 mg tab.
Biotechnology to Combat COVID-19
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9. Conclusion
In this review we have concluded that the treatment of the viral infection 
and current covid 19 includes the combination therapy of antiviral drugs and 
the immune modeling drugs. Use of the antiviral drugs for the treatment of viral 
infection prevents from illness and as well as mortality rate. Lot of clinical trails are 
going on to prove their efficacy against SARS-CoV-2 and will definitely prove to be 
fruitful and help to save the human community.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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